PROTEUS SYNDROME: NEED FOR PATIENT CENTRIC THERAPY

Authors

  • Gowthamarajan Kuppusamy Department of Pharmaceutics, JSS College of Pharmacy (Udhagamund), JSS Academy of Higher Education and Research, Mysuru, Karnataka, India.
  • Arun Radhakrishnan Department of Pharmaceutics, JSS College of Pharmacy (Udhagamund), JSS Academy of Higher Education and Research, Mysuru, Karnataka, India.
  • Nikhitha K Shanmukhan Department of Pharmaceutics, JSS College of Pharmacy (Udhagamund), JSS Academy of Higher Education and Research, Mysuru, Karnataka, India.
  • Prineethaa M Department of Pharmaceutics, JSS College of Pharmacy (Udhagamund), JSS Academy of Higher Education and Research, Mysuru, Karnataka, India.
  • Anusha S Department of Pharmaceutics, JSS College of Pharmacy (Udhagamund), JSS Academy of Higher Education and Research, Mysuru, Karnataka, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i12.28028

Keywords:

Proteus syndrome, AKT1 gene, Pathophysiology, Symptoms, Diagnosis, Generalized and personalized treatment

Abstract

Proteus syndrome (PS) is a hamartomatous disorder with multisystem involvement that results from mutation in the AKT1gene. Since the symptoms and severity of PS are unique to each patient, diagnosis and treatment become hard for the physician. This article is concentrated upon the identification and recognition of specific characteristics of the disease, pathophysiology, symptoms, diagnosis, treatment and the necessity of advanced diagnosis, effective generalized and personalized therapy, as well as the requirement of new drugs for the management of PS. Detailed studies on the PS and evidence from the case reports revealed the requirement of intensive care, accurate diagnosis, and an effective treatment for each patient preferably patient-centric drug delivery due to the high degree of variation in the symptoms and clinical features among patients.

Downloads

Download data is not yet available.

Author Biography

Arun Radhakrishnan, Department of Pharmaceutics, JSS College of Pharmacy (Udhagamund), JSS Academy of Higher Education and Research, Mysuru, Karnataka, India.

Pharmaceutics

References

Wieland I, Tinschert S, Zenker M. High-level somatic mosaicism of AKT1 c. 49G> A mutation in skin scrapings from epidermal nevi enables non-invasive molecular diagnosis in patients with Proteus syndrome. Am J Med Genet A 2013;161:889-91.

Parikh C, Janakiraman V, Wu WI, Foo CK, Kljavin NM, Chaudhuri S, et al. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc Natl Acad Sci U S A 2012;109:19368-73.

Dalal AB, Phadke SR, Pradhan M, Sharda S. Hemihyperplasia syndromes. Indian J Pediatr 2006;73:609-15.

Cohen MM Jr., Hayden PW. A newly recognized hamartomatous syndrome. Birth Defects Orig Artic Ser 1979;15:291-6.

Gordon PL, Wilroy RS, Lasater OE, Cohen MM Jr. Neoplasms in Proteus syndrome. Am J Med Genet 1995;57:74-8.

Smith JM, Kirk EP, Theodosopoulos G, Marshall GM, Walker J, Rogers M, et al. Germline mutation of the tumour suppressor PTEN in Proteus syndrome. J Med Genet 2002;39:937-40.

Harper J, Giehl K, Hennekam R. Proteus Syndrome. Harper’s Textbook of Pediatric Dermatology, Volume 1, 2. 3rd ed. Lou- Isiana, New Orleans: Butterworths; 1993. p. 111.

Sherzay N, Chitakar E. Epigenetics: Effect of environmental factors on human genome. Int J Pharm Pharm Sci 2016;8:1-6.

Proteus syndrome. Genetics home reference. Available from: https://www.ghr.nlm.nih.gov/condition/proteus-syndrome#statistics.

Yi KH, Lauring J. Recurrent AKT mutations in human cancers: Functional consequences and effects on drug sensitivity. Oncotarget 2016;7:4241-51.

Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 2011;365:611-9.

Türk CY, Güney A, Oner M, Halıcı M. An unusual initial presentation of Proteus syndrome: Macrosyndactyly. Eklem Hastalik Cerrahisi 2011;22:56-9.

Beachkofsky TM, Sapp JC, Biesecker LG, Darling TN. Progressive overgrowth of the cerebriform connective tissue nevus in patients with Proteus syndrome. J Am Acad Dermatol 2010;63:799-804.

Hagari Y, Aso M, Shimao S, Okano T, Kurimasa A, Takeshita K, et al. Proteus syndrome: Report of the first Japanese case with special reference to differentiation from Klippel-trenaunay-weber syndrome. J Dermatol 1992;19:477-80.

Rodenbeck DL, Greyling LA, Anderson JH, Davis LS. Early recognition of Proteus syndrome. Pediatr Dermatol 2016;33:e306-10.

Happle R. The manifold faces of Proteus syndrome. Arch Dermatol 2004;140:1001-2.

Martínez-Glez V, Romanelli V, Mori MA, Gracia R, Segovia M, González-Meneses A, et al. Macrocephaly-capillary malformation: Analysis of 13 patients and review of the diagnostic criteria. Am J Med Genet A 2010;152A:3101-6.

Asilian A, Kamali AS, Riahi NT, Adibi N, Mokhtari F. Proteus syndrome with arteriovenous malformation. Adv Biomed Res 2017;6:27.

Biesecker LG, Happle R, Mulliken JB, Weksberg R, Graham JM Jr., Viljoen DL, et al. Proteus syndrome: Diagnostic criteria, differential diagnosis, and patient evaluation. Am J Med Genet 1999;84:389-95.

Nerkar DA, Mukherjee AN, Mehta BK, Banerjee SU. Metabolic syndrome associated complications. Int J Pharm Pharm Sci 2015;7:22 5.

Romano C, Schepis C. PTEN gene: A model for genetic diseases in dermatology. Sci World J 2012;2012:252457.

Elsayes KM, Menias CO, Dillman JR, Platt JF, Willatt JM, Heiken JP, et al. Vascular malformation and hemangiomatosis syndromes: Spectrum of imaging manifestations. AJR Am J Roentgenol 2008;190:1291-9.

Cohen MM Jr., Proteus syndrome review: Molecular, clinical, and pathologic features. Clin Genet 2014;85:111-9.

Cohen MM. Proteus syndrome: An update. Am J Med Genet Part C: Semin Med Genet 2005;137:38-52.

Barry M, Wilson WG. Proteus Syndrome Treatment and Management. U.S: Medscape; 2016.

Adams DM, Trenor CC 3rd, Hammill AM, Vinks AA, Patel MN, Chaudry G, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics 2016;137:e20153257.

Biesecker LG. The multifaceted challenges of Proteus syndrome. JAMA 2001;285:2240-3.

Loffeld A, McLellan NJ, Cole T, Moss C. Type 2 segmental Cowden disease vs. Proteus syndrome: Reply from authors. Br J Dermatol 2008;158:410-1.

Gilbert-Barness E, Cohen MM Jr., Opitz JM. Multiple meningiomas, craniofacial hyperostosis and retinal abnormalities in Proteus syndrome. Am J Med Genet 2000;93:234-40.

Skovby F, Graham JM Jr. Sonne-Holm S, Cohen MM Jr. Compromise of the spinal canal in Proteus syndrome. Am J Med Genet 1993;47:656 9.

Lacombe D, Battin J. Isolated macrodactyly and Proteus syndrome. Clin Dysmorphol 1996;5:255-7.

De Becker I, Gajda DJ, Gilbert-Barness E, Cohen MM Jr. Ocular manifestations in Proteus syndrome. Am J Med Genet 2000;92:350-2.

Slavotinek AM, Vacha SJ, Peters KF, Biesecker LG. Sudden death caused by pulmonary thromboembolism in Proteus syndrome. Clin Genet 2000;58:386-9.

Mohamedbhai AG, Hassan Miyan AM, Lacombe D. Neonatal Proteus syndrome? Am J Med Genet 2002;112:228-30.

Valéra MC, Vaysse F, Bieth E, Longy M, Cances C, Bailleul-Forestier I, et al. Proteus syndrome: Report of a case with AKT1 mutation in a dental cyst. Eur J Med Genet 2015;58:300-4.

Rocha RC, Estrella MP, Amaral DMD, Barbosa AM, Abreu MA. Proteus syndrome. An Bras Dermatol 2017;92:717-20.

Peters KF, Biesecker LG. An opportunity for genetic counseling intervention: Depression in parents of individuals with Proteus syndrome. J Genet Couns 2000;9:161-71.

Batra P, Duggal R, Parkash H. Craniofacial and dental manifestations of a case of proteus syndrome. J Indian Soc Pedod Prev Dent 2004;22:154 7.

National Institutes of Health Clinical Center. Dose Finding Study of ARQ092 in Childrens and Adults with Proteus Syndrome. U.S: National Institutes of Health Clinical Center (CC).

Reza MI, Goel D, Rahman Z, Aamer S. Microrna and RNA binding proteins: The posttranscriptional regulators of foxo expression. J Crit Rev 2018;5:1-9.

Marsh DJ, Trahair TN, Martin JL, Chee WY, Walker J, Kirk EP, et al. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol 2008;5:357-61.

Suzuki Y, Enokido Y, Yamada K, Inaba M, Kuwata K, Hanada N, et al. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS). Oncotarget 2017;8:45470-83.

Sene LS, Sales PD, Chojniak R. Proteus syndrome: Case report. Revista da Associação Médica Brasileira 2013;59:318-20.

Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab 2016;23:1060-5.

Lindhurst MJ, Yourick MR, Yu Y, Savage RE, Ferrari D, Biesecker LG, et al. Repression of AKT signaling by ARQ 092 in cells and tissues from patients with proteus syndrome. Sci Rep 2015;5:17162.

Lublin M, Schwartzentruber DJ, Lukish J, Chester C, Biesecker LG, Newman KD, et al. Principles for the surgical management of patients with Proteus syndrome and patients with overgrowth not meeting proteus criteria. J Pediatr Surg 2002;37:1013-20.

Bunker JP. Surgical manpower. A comparison of operations and surgeons in the United States and in England and Wales. N Engl J Med 1970;282:135-44.

Wenz W, Berrsche G. Proteus syndrome: Surgical treatment in foot and ankle. Tech Foot Ankle Surg 2014;13:206-11.

Cassidy SB, McCandless SE. In: Cassidy SB, Allanson JE, editors. Prader-Willi Syndrome In: Management of Genetic Syndromes. New York: John Wiley and Sons; 2005. p. 429-48.

Biesecker L. Proteus Syndrome. NORD Guide to Rare Disorders. Philadelphia, PA: Lippincott Williams and Wilkins; 2003. p. 239.

Devi S, Singh K. Risk factors, prevalence and diagnosis of Hutchison gilford syndrome with special reference to case reports. J Pharm Pharm Sci 2016;915:16282.

Zhang XB, Li CX, He YQ, Zhang SQ, Cai YX. Proteus syndrome: A case report and a case study review in china. Dermatol Reports 2010;2:e3.

Popescu MD, Burnei G, Draghici L, Draghici I. Proteus syndrome: A difficult diagnosis and management plan. J Med Life 2014;7:563-6.

Ou M, Sun Z, Zhu P, Sun G, Dai Y. Proteus syndrome: A case report and review of the literature. Mol Clin Oncol 2017;6:381-3.

Satter E. Proteus syndrome: 2 case reports and a review of the literature. Cutis 2007;80:297-302.

Vasquez L, Tello M, Maza I, Oscanoa M, Dueñas M, Castro H, et al. Endometrioid paraovarian borderline cystic tumor in an infant with Proteus syndrome. Case Rep Oncol Med 2015;2015:392576.

Ference T, Fertig RM, Feldman M, Jacobs J, Casella G, Mena J. Rehabilitation of a patient with Proteus syndrome case report and literature review. J Clin Med Ther 2017;2:16.

Published

07-12-2018

How to Cite

Kuppusamy, G., A. Radhakrishnan, N. K Shanmukhan, P. M, and A. S. “PROTEUS SYNDROME: NEED FOR PATIENT CENTRIC THERAPY”. Asian Journal of Pharmaceutical and Clinical Research, vol. 11, no. 12, Dec. 2018, pp. 27-32, doi:10.22159/ajpcr.2018.v11i12.28028.

Issue

Section

Review Article(s)

Most read articles by the same author(s)